News for Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma's (CANF) Phase IIa pancreatic cancer trial has achieved 50% enrollment. Namodenoson, the focus of the trial, has demonstrated a favor

**media[614545]**

FDA grants compassionate use approval for Namodenoson in pancreatic carcinoma. Increased interest from leading U.S. medical centers pursuing sim

**media[598252]**

Can-Fite BioPharma Ltd. announces a $3.0 million registered direct offering of American Depositary Shares (ADSs). The company will issue 2,500,000 ADSs

**media[594839]**

Can-Fite BioPharma (CANF) projects $685 million in revenue from partnerships over the next decade. The forecast covers key drug candidates targeting pso

Can-Fite BioPharma (CANF) reports a notable complete cancer remission in a liver cancer patient treated with Namodenoson. Namodenoson receives FDA Orpha

**media[594431]**

**media[572110]**

**media[569569]**

**media[555161]**

**media[543136]**

**media[532710]**

Can Fite Biopharma stock hits 52-week low at $1.86

**media[483114]**

ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma

Can-Fite secures Australian patent for obesity treatment

Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd....